Publications by authors named "Matthias Bichler"
Article Synopsis
- Somatic evolution of cancer genomes leads to different subclones that may affect treatment resistance and offer new therapeutic options in metastatic breast cancer.
- A study analyzed circulating tumor DNA from 46 patients before and after treatment, looking for new mutations that arise during therapy.
- The results showed that while the number of new mutations did not significantly differ between treatment groups overall, the occurrence of new mutations varied significantly among secondary resistant patients depending on whether they received chemotherapy, a combination of chemotherapy and CE maintenance treatment, or solely CE therapy.
- Further research is needed with larger patient groups to confirm these findings.
Introduction: Cyclin-dependent 4/6 kinase (CDK4/6) inhibitors given with endocrine therapy until disease progression are standard of care in the treatment of women with advanced HR-positive Her-2-negative breast cancer. No data are available if therapy can be safely de-escalated to endocrine monotherapy in patients with long-lasting disease control.
Methods: We performed a retrospective analysis on the clinical course of 22 patients at our center who received CDK4/6 inhibitors with aromatase inhibitors or fulvestrant.